Abstract: Abstract：To observe the clinical effect of Feishu capsule which has been renamed Shengeyifei capsule（drug approval number Z20080756） on the steady stage period of COPD. Methods: With randomized, single blinded trial 87 patients with steady stage period of COPD were randomized divided in two groups. One is the cure group(44 cases) and the other is the control group(43 cases). Indexes evaluated were following: indexes (syndrome in TCM , pulmonary function, ratio of FEV1／FVC, BODE ,BMI, air current obstruct degree (O，FEV1%pred),dyspnea (D，MMRC))， movement resistance （E，6MWT）。Result: the effective rate of syndrome indexes in TCM is 88.64%,the control group is 67．44％ (P＜0.05)；pulmonary function （FEV1％、FEV1／FVC）were increased significantly after treatment compared with that before(P＜0．05) in cure group, there was no difference in control group(P>0．05). the cure group was elevated compared with the control group after the treatment (P＜0．05) ;BODE indexes were decreased significantly after treatment compared with that before(P＜0．05) in cure group, there was no difference in control group(P>0．05). the cure group was decreased compared with the control group after the treatment (P＜0．05)。Conclusion: The elemental research indicates Feishu capsule on the steady stage period of COPD has probably advantages in improvement of syndrome indexes in TCM, pulmonary function, BODE indexes and personal living ability.

Key words: Feishu capsule, the steady stage period of COPD, clinical effect, pulmonary function, BODE indexes